Rafael Holdings, Inc. (RFL)
$
1.36
+0.01 (0.74%)
Key metrics
Financial statements
Free cash flow per share
-0.4541
Market cap
47.7 Million
Price to sales ratio
65.1387
Debt to equity
0.0086
Current ratio
3.8480
Income quality
0.4878
Average inventory
144 Thousand
ROE
-0.2996
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Rafael Holdings, Inc. operates in the pharmaceuticals and real estate sectors, holding interests in clinical and early-stage pharmaceutical companies as well as commercial real estate assets in the United States and Israel. The company engages in the leasing of a commercial office building alongside an 800-car public garage, while also focusing on the development and commercialization of therapies targeting the metabolic disparities between normal and cancerous cells. The earnings per share (EPS) is reported at -$1.45 indicating the company's profitability on a per-share basis. Additionally, the operating expenses amount to $103,110,000.00 encompassing a variety of operational costs incurred by the firm. The net total of other income and expenses is $35,366,000.00 reflecting its non-core financial activities. A crucial measure of its financial health, the EBITDA is -$66,788,000.00 representing the company's operational profitability. Moreover, the operating income ratio is -$161.11 which showcases the company's operational profitability margin as it aims to enhance its market position through innovative therapies. The company’s lead drug candidate, CPI-613 (devimistat), is undergoing various clinical studies, including two Phase III registrational trials targeting metastatic pancreatic cancer and relapsed/refractory acute myeloid leukemia, solidifying its commitment to addressing critical health challenges. On the market front, Rafael Holdings presents a stock that is affordable at $1.44 making it an appealing option for budget-conscious investors. However, the stock has a low average trading volume of 112,234.00 indicating lower market activity, which could affect liquidity. With a market capitalization of $47,727,068.00 the company is classified as a small-cap player in the industry, where it is recognized as a key contributor to the overall market landscape. It operates within the Real Estate sector, driving innovation and growth, and highlighting its strategic focus on creating therapies that promise to significantly improve patient outcomes. By maintaining its position in this dynamic industry, Rafael Holdings continues to attract attention from investors seeking exposure to both pharmaceuticals and real estate opportunities, which together form a robust portfolio aimed at long-term value creation.
Is Rafael Holdings, Inc. (RFL) a good investment?
Investing in Rafael Holdings, Inc. (RFL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Rafael Holdings, Inc. (RFL)'s stock forecast?
Analysts predict Rafael Holdings, Inc. stock to fluctuate between $1.28 (low) and $3.19 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Rafael Holdings, Inc.'s market capitalization?
As of 2025-10-31, Rafael Holdings, Inc.'s market cap is $47,727,068, based on 35,093,432 outstanding shares.
How does Rafael Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Rafael Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Rafael Holdings, Inc. pay dividends?
Rafael Holdings, Inc. pays dividends. The current dividend yield is 0.82%, with a payout of $0.02 per share.
How can I buy Rafael Holdings, Inc. (RFL) stock?
To buy Rafael Holdings, Inc. (RFL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for RFL. Place an order (Market, Limit, etc.).
What is the best time to invest in Rafael Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Rafael Holdings, Inc. stock ever split?
Rafael Holdings, Inc.'s last stock split was 507:500 on 2025-05-09.
How did Rafael Holdings, Inc. perform in the last earnings report?
Revenue: $637,000 | EPS: -$1.45 | Growth: 1,699.01%.
Where can I find Rafael Holdings, Inc.'s investor relations reports?
Visit https://www.rafaelholdings.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Rafael Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Rafael Holdings, Inc. stock?
All-time high: $56 (2021-08-06) | All-time low: $1.28 (2025-05-21).
What are the key trends affecting Rafael Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks
globenewswire.com
Vancouver B.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- TERRA CLEAN ENERGY CORP. (“Terra” or the “Company”) (CSE: TCEC, OTCQB: TCEFF , FSE: C 9O0), is pleased to announce that, further to its press release dated September 16, 2025, and to clarity the press release issued earlier today, it has entered into definitive agreements with arm's length parties to acquire up to a 100% interest in each of the Wheel Anne Claims and the Green Vein Mesa Claims (each of the properties are located in Emery County, Utah, United States).
globenewswire.com
Vancouver B.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- TERRA CLEAN ENERGY CORP. (“Terra” or the “Company”) (CSE: TCEC, OTCQB: TCEFF , FSE: C 9O0), is pleased to announce that, further to its press release dated September 16, 2025, it has entered into definitive agreements with arm's length parties to acquire up to a 100% interest in each of the Wheel Anne Claims and the Green Vein Mesa Claims (each of the properties are located in Emery County, Utah, United States).
thenewswire.com
Vancouver B.C. - TheNewswire - September 24, 2025 – TERRA CLEAN ENERGY CORP. (“ Terra ” or the “ Company ”) (CSE: TCEC, OTCQB: TCEFF , FSE: C 9O0) , is pleased to announce that, further to its press release dated September 16, 2025, it has entered into definitive agreements with arm's length parties to acquire up to a 100% interest in each of the Wheel Anne Claims and the Green Vein Mesa Claims (each of the properties are located in Emery County, Utah, United States). “The quick execution of the agreements shows the Company's commitment and excitement to these assets and to our already significant portfolio of low-risk uranium assets in world renowned uranium basins" state Greg Cameron, CEO of Terra. “Our plan is to have our team on the ground in Utah in the coming weeks working closely with our local partner.”
globenewswire.com
Vancouver B.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- TERRA CLEAN ENERGY CORP. (“Terra” or the “Company”) (CSE: TCEC, OTCQB: TCEFF , FSE: 9O0), is pleased to announce terms to acquire up to a 100% interest in 75 uranium claims in Emery County, Utah, United States.
thenewswire.com
Vancouver B.C. – TheNewswire - September 16, 2025 – TERRA CLEAN ENERGY CORP. (“ Terra ” or the “ Company ”) (CSE: TCEC, OTCQB: TCEFF, FSE: 9O0 , is pleased to announce terms to acquire up to a 100% interest in 75 uranium claims in Emery County, Utah, United States. Transaction Highlights
prnewswire.com
DALLAS , Aug. 20, 2025 /PRNewswire/ -- Texas Instruments Incorporated (TI) (Nasdaq: TXN) Senior Vice President and Chief Financial Officer Rafael Lizardi will speak at the Citi 2025 Global TMT Conference in New York City on Thursday, Sept. 4, at 8:10 a.m.
prnewswire.com
DALLAS , May 19, 2025 /PRNewswire/ -- Texas Instruments Incorporated (TI) (Nasdaq: TXN) Senior Vice President and Chief Financial Officer Rafael Lizardi will speak at the Bank of America 2025 Global Technology Conference in San Francisco on Wednesday, June 4, at 11:20 a.m. Pacific time.
globenewswire.com
NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants (“Holders”) the opportunity to purchase additional shares of Rafael Holdings' Class B common stock, par value $0.01 per share (“Class B Common Stock”), subject to the terms outlined below for an aggregate offering of $25 million. The funds provide the Company additional capital for the potential launch of Trappsol® Cyclo™ in the event of a positive interim result from the 48-week interim analysis of the TransportNPC™ Phase 3 clinical trial in Niemann-Pick Disease Type C1 (“NPC1”).
globenewswire.com
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
See all news
